Does the media refer more to ATRA or ORIC?

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for Oric Pharmaceuticals and 1 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.33 beat Atara Biotherapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oric Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ATRA or LYEL?

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 1 articles in the media. Lyell Immunopharma's average media sentiment score of 0.83 beat Atara Biotherapeutics' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ATRA or ZNTL?

In the previous week, Zentalis Pharmaceuticals had 7 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 8 mentions for Zentalis Pharmaceuticals and 1 mentions for Atara Biotherapeutics. Zentalis Pharmaceuticals' average media sentiment score of 0.52 beat Atara Biotherapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zentalis Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PALI or ATRA?

In the previous week, Palisade Bio and Palisade Bio both had 1 articles in the media. Palisade Bio's average media sentiment score of 1.34 beat Atara Biotherapeutics' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atara Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Atara Biotherapeutics (ATRA) Competitors

$8.13 -0.50 (-5.79%)

As of 07/22/2026 04:00 PM Eastern

Compare

ATRA vs. ORIC, LYEL, FHTX, ZNTL, and PALI

Should you buy Atara Biotherapeutics stock or one of its competitors? MarketBeat compares Atara Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Lyell Immunopharma (LYEL), Foghorn Therapeutics (FHTX), Zentalis Pharmaceuticals (ZNTL), and Palisade Bio (PALI). These companies are all part of the "pharmaceutical products" industry.

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Oric Pharmaceuticals had 2 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 3 mentions for Oric Pharmaceuticals and 1 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 0.33 beat Atara Biotherapeutics' score of 0.00 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oric Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Atara Biotherapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

Atara Biotherapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 16.85%. Oric Pharmaceuticals has a consensus price target of $19.27, suggesting a potential upside of 79.28%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Oric Pharmaceuticals' return on equity of -35.33% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$23.14M	3.17	$32.69M	-$0.67	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

Summary

Oric Pharmaceuticals beats Atara Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Lyell Immunopharma?

Atara Biotherapeutics (NASDAQ:ATRA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 6.2% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Atara Biotherapeutics presently has a consensus price target of $9.50, indicating a potential upside of 16.85%. Lyell Immunopharma has a consensus price target of $43.20, indicating a potential upside of 236.45%. Given Lyell Immunopharma's stronger consensus rating and higher possible upside, analysts plainly believe Lyell Immunopharma is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Atara Biotherapeutics has a net margin of -40.91% compared to Lyell Immunopharma's net margin of -794,858.12%. Atara Biotherapeutics' return on equity of -79.12% beat Lyell Immunopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Atara Biotherapeutics has higher revenue and earnings than Lyell Immunopharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$23.14M	3.17	$32.69M	-$0.67	N/A
Lyell Immunopharma	$40K	7,864.50	-$274.45M	-$13.80	N/A

Atara Biotherapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.06, meaning that its share price is 106% less volatile than the broader market.

In the previous week, Atara Biotherapeutics and Atara Biotherapeutics both had 1 articles in the media. Lyell Immunopharma's average media sentiment score of 0.83 beat Atara Biotherapeutics' score of 0.00 indicating that Lyell Immunopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lyell Immunopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Atara Biotherapeutics beats Lyell Immunopharma on 9 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Foghorn Therapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 16.85%. Foghorn Therapeutics has a consensus price target of $11.43, suggesting a potential upside of 119.36%. Given Foghorn Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Foghorn Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Foghorn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 9.0% of Foghorn Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Atara Biotherapeutics has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Foghorn Therapeutics has a beta of 2.86, suggesting that its share price is 186% more volatile than the broader market.

Atara Biotherapeutics has a net margin of -40.91% compared to Foghorn Therapeutics' net margin of -266.88%. Foghorn Therapeutics' return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Foghorn Therapeutics	-266.88%	N/A	-35.38%

Atara Biotherapeutics has higher earnings, but lower revenue than Foghorn Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$23.14M	3.17	$32.69M	-$0.67	N/A
Foghorn Therapeutics	$30.91M	9.90	-$74.28M	-$1.16	N/A

In the previous week, Atara Biotherapeutics had 1 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 1 mentions for Atara Biotherapeutics and 0 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.63 beat Atara Biotherapeutics' score of 0.00 indicating that Foghorn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
Foghorn Therapeutics	Very Positive

Summary

Foghorn Therapeutics beats Atara Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Zentalis Pharmaceuticals?

Atara Biotherapeutics (NASDAQ:ATRA) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, media sentiment, dividends, analyst recommendations, risk and institutional ownership.

Atara Biotherapeutics has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$23.14M	3.17	$32.69M	-$0.67	N/A
Zentalis Pharmaceuticals	$67.43M	4.75	-$137.06M	-$1.73	N/A

Atara Biotherapeutics presently has a consensus price target of $9.50, suggesting a potential upside of 16.85%. Zentalis Pharmaceuticals has a consensus price target of $6.75, suggesting a potential upside of 50.00%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33

70.9% of Atara Biotherapeutics shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by company insiders. Comparatively, 3.8% of Zentalis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Atara Biotherapeutics has a beta of 0.08, suggesting that its stock price is 92% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

Zentalis Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Zentalis Pharmaceuticals' return on equity of -53.61% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Zentalis Pharmaceuticals	N/A	-53.61%	-40.67%

In the previous week, Zentalis Pharmaceuticals had 7 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 8 mentions for Zentalis Pharmaceuticals and 1 mentions for Atara Biotherapeutics. Zentalis Pharmaceuticals' average media sentiment score of 0.52 beat Atara Biotherapeutics' score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zentalis Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zentalis Pharmaceuticals beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

How does Atara Biotherapeutics compare to Palisade Bio?

Palisade Bio (NASDAQ:PALI) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Palisade Bio and Palisade Bio both had 1 articles in the media. Palisade Bio's average media sentiment score of 1.34 beat Atara Biotherapeutics' score of 0.00 indicating that Palisade Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palisade Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atara Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palisade Bio has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Palisade Bio presently has a consensus target price of $9.00, indicating a potential upside of 373.68%. Atara Biotherapeutics has a consensus target price of $9.50, indicating a potential upside of 16.85%. Given Palisade Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Palisade Bio is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palisade Bio	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 0.1% of Palisade Bio shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Palisade Bio. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palisade Bio	$250K	1,319.21	-$16.78M	-$1.01	N/A
Atara Biotherapeutics	$23.14M	3.17	$32.69M	-$0.67	N/A

Palisade Bio has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Palisade Bio's return on equity of -36.79% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palisade Bio	N/A	-36.79%	-34.34%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Summary

Palisade Bio beats Atara Biotherapeutics on 11 of the 16 factors compared between the two stocks.

Get Atara Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRA vs. The Competition

Export

Metric	Atara Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$77.76M	$3.68B	$7.01B	$12.68B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	-12.13	21.19	26.82	23.95
Price / Sales	3.17	306.01	577.59	115.11
Price / Cash	1.77	155.65	50.60	60.45
Price / Book	-1.52	8.00	10.39	6.16
Net Income	$32.69M	$23.81M	$3.60B	$331.73M
7 Day Performance	-6.77%	-1.22%	-1.37%	-0.92%
1 Month Performance	-27.15%	-1.36%	-0.31%	-2.23%
1 Year Performance	-33.69%	34.77%	18.94%	14.79%

Atara Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRA Atara Biotherapeutics	2.0453 of 5 stars	$8.13 -5.8%	$9.50 +16.9%	-37.6%	$77.76M	$23.14M	N/A	330	News Coverage
ORIC Oric Pharmaceuticals	1.8524 of 5 stars	$10.46 -3.6%	$19.27 +84.3%	-3.6%	$1.12B	N/A	N/A	80	Positive News
LYEL Lyell Immunopharma	3.9128 of 5 stars	$14.33 -4.5%	$43.00 +200.1%	+24.9%	$350.24M	$40K	N/A	270	News Coverage Analyst Forecast Gap Up
FHTX Foghorn Therapeutics	3.0138 of 5 stars	$5.44 -8.6%	$11.43 +110.1%	-17.8%	$349.35M	$30.91M	N/A	120
ZNTL Zentalis Pharmaceuticals	2.6161 of 5 stars	$4.62 -5.3%	$5.83 +26.3%	+214.7%	$347.39M	$67.43M	N/A	160	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRA) was last updated on 7/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, LYEL, FHTX, ZNTL, and PALI

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Lyell Immunopharma?

Summary

How does Atara Biotherapeutics compare to Foghorn Therapeutics?

Summary

How does Atara Biotherapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Atara Biotherapeutics compare to Palisade Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atara Biotherapeutics (ATRA) Competitors

ATRA vs. ORIC, LYEL, FHTX, ZNTL, and PALI

How does Atara Biotherapeutics compare to Oric Pharmaceuticals?

Does the media refer more to ATRA or ORIC?

Do insiders and institutionals hold more shares of ATRA or ORIC?

Which has more volatility & risk, ATRA or ORIC?

Do analysts prefer ATRA or ORIC?

Is ATRA or ORIC more profitable?

Which has better earnings & valuation, ATRA or ORIC?

Summary

How does Atara Biotherapeutics compare to Lyell Immunopharma?

Do insiders & institutionals believe in ATRA or LYEL?

Do analysts recommend ATRA or LYEL?

Is ATRA or LYEL more profitable?

Which has preferable earnings & valuation, ATRA or LYEL?

Which has more risk & volatility, ATRA or LYEL?

Does the media prefer ATRA or LYEL?

Summary

How does Atara Biotherapeutics compare to Foghorn Therapeutics?

Do analysts recommend ATRA or FHTX?

Do insiders and institutionals hold more shares of ATRA or FHTX?

Which has more risk and volatility, ATRA or FHTX?

Is ATRA or FHTX more profitable?

Which has higher earnings & valuation, ATRA or FHTX?

Does the media refer more to ATRA or FHTX?

Summary

How does Atara Biotherapeutics compare to Zentalis Pharmaceuticals?

Which has better valuation and earnings, ATRA or ZNTL?

Do analysts recommend ATRA or ZNTL?

Do institutionals and insiders hold more shares of ATRA or ZNTL?

Which has more risk & volatility, ATRA or ZNTL?

Is ATRA or ZNTL more profitable?

Does the media refer more to ATRA or ZNTL?

Summary

How does Atara Biotherapeutics compare to Palisade Bio?

Does the media prefer PALI or ATRA?

Which has more risk & volatility, PALI or ATRA?

Do analysts rate PALI or ATRA?

Do insiders and institutionals hold more shares of PALI or ATRA?

Which has higher earnings and valuation, PALI or ATRA?

Is PALI or ATRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATRA vs. The Competition

Atara Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools